Gilead Sciences stock declined Wednesday after The Wall Street Journal reported the Department of Health and Human Services was considering federal funding cuts to domestic HIV prevention. The Centers for Disease Control and Prevention,

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their HIV divisions, according to analysts.